HomeCompareNTBL vs JEPQ

NTBL vs JEPQ: Dividend Comparison 2026

NTBL yields 806.78% · JEPQ yields 11.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NTBL wins by $2978922.51M in total portfolio value
10 years
NTBL
NTBL
● Live price
806.78%
Share price
$0.25
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2978922.56M
Annual income
$2,394,962,626,110.49
Full NTBL calculator →
JEPQ
JPMorgan Nasdaq Equity Premium Income ETF
● Live price
11.10%
Share price
$55.52
Annual div
$6.16
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.8K
Annual income
$2,152.59
Full JEPQ calculator →

Portfolio growth — NTBL vs JEPQ

📍 NTBL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNTBLJEPQ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NTBL + JEPQ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NTBL pays
JEPQ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NTBL
Annual income on $10K today (after 15% tax)
$68,576.04/yr
After 10yr DRIP, annual income (after tax)
$2,035,718,232,193.92/yr
JEPQ
Annual income on $10K today (after 15% tax)
$943.83/yr
After 10yr DRIP, annual income (after tax)
$1,829.70/yr
At 15% tax rate, NTBL beats the other by $2,035,718,230,364.22/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NTBL + JEPQ for your $10,000?

NTBL: 50%JEPQ: 50%
100% JEPQ50/50100% NTBL
Portfolio after 10yr
$1489461.30M
Annual income
$1,197,481,314,131.53/yr
Blended yield
80.40%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NTBL right now

NTBL
Analyst Ratings
1
Buy
1
Hold
Consensus: Buy
Altman Z
-15.3
Piotroski
1/9
JEPQ
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NTBL buys
0
JEPQ buys
0
No recent congressional trades found for NTBL or JEPQ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNTBLJEPQ
Forward yield806.78%11.10%
Annual dividend / share$2.00$6.16
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$2978922.56M$44.8K
Annual income after 10y$2,394,962,626,110.49$2,152.59
Total dividends collected$2932808.83M$16.3K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: NTBL vs JEPQ ($10,000, DRIP)

YearNTBL PortfolioNTBL Income/yrJEPQ PortfolioJEPQ Income/yrGap
1← crossover$91,378$80,677.69$11,930$1,110.39+$79.4KNTBL
2$786,759$688,985.18$14,133$1,224.34+$772.6KNTBL
3$6,385,891$5,544,058.49$16,632$1,340.46+$6.37MNTBL
4$48,888,484$42,055,580.67$19,454$1,457.97+$48.87MNTBL
5$353,212,577$300,901,898.82$22,626$1,576.08+$353.19MNTBL
6$2,409,689,660$2,031,752,203.28$26,175$1,694.09+$2409.66MNTBL
7$15,532,607,283$12,954,239,346.30$30,133$1,811.32+$15532.58MNTBL
8$94,658,834,336$78,038,944,543.74$34,531$1,927.17+$94658.80MNTBL
9$545,756,944,763$444,471,992,023.36$39,403$2,041.08+$545756.91MNTBL
10$2,978,922,557,007$2,394,962,626,110.49$44,787$2,152.59+$2978922.51MNTBL

NTBL vs JEPQ: Complete Analysis 2026

NTBLStock

Notable Labs, Ltd., a clinical-stage platform therapeutics company, engages in developing predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient is likely to respond to that specific therapeutic. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and thus fast-track clinical development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor for acute myeloid leukemia (AML), pediatric leukemia, and myelodysplastic syndromes indications; and Fosciclopirox, a pro-drug of ciclopirox for AML. Notable Labs, Ltd. is headquartered in Foster City, California.

Full NTBL Calculator →

JEPQETF

The fund seeks to achieve this objective by (1) creating an actively managed portfolio of equity securities comprised significantly of those included in the fund’s primary benchmark, the Nasdaq-100 Index (the Benchmark), and (2) through equity-linked notes (ELNs), selling call options with exposure to the Benchmark. It is non-diversified.

Full JEPQ Calculator →
📬

Get this NTBL vs JEPQ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NTBL vs SCHDNTBL vs JEPINTBL vs ONTBL vs KONTBL vs MAINNTBL vs XYLDNTBL vs QYLDNTBL vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.